Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Gland Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1676.6, down 1.75% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.68% on the day, quoting at 24597.8. The Sensex is at 79386.06, down 0.79%.Gland Pharma Ltd has eased around 11.05% in last one month.Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has increased around 3.44% in last one month and is currently quoting at 23005.5, up 0.23% on the day. The volume in the stock stood at 50035 shares today, compared to the daily average of 84591 shares in last one month.
The PE of the stock is 23.67 based on TTM earnings ending December 25.
Shares of Sammaan Capital are banned from F&O trading on Wednesday 04 March 2026.
Stocks to Watch:
Oil sensitive stocks will continue to remain as tensions in West Asia persist.
Adani Ports & Special Economic Zone (APSEZ) handled 42.5 MT in February 2026, registering the growth of 16% YoY. Logistics rail volume stood at 52,101 TEUs in February 2026, up 3% YoY.
Natco Pharma along with its partner Breckenridge Pharmaceutical, Inc announces launch of Pomalidomide Capsules. The said drug is indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies
Gland Pharma’s chief executive officer(CEO), Shyamakant Giri, has resigned from the position with effect from 30 April 2026.
Juniper Hotels has received letter of award (LoA) from Delhi Development Authority (DDA) to develop 5 star hotel property on licensed land parcel in Dwarka, New Delhi
Allied Blenders and Distillers' board approved to acquire upto 50% stake in Kion Blenders Industries for total consideration of Rs 45 crore.
JSW Cement has been declared as the preferred bidder for the mining lease of the Sikilangso Limestone Block (Part A & Part B) located in Umrangso, Dima Hasao District, Assam.
Gland Pharma has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC).
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Lumify Ophthalmic Solution, 0.025%, of Bausch & Lomb Inc.
This Product is indicated to relieve redness of the eye.
Brimonidine Tartrate Ophthalmic Solution, 0.025% is indicated for the relief of redness of the eye. According to IQVIA data, the product recorded US sales of approximately $39 million for the twelve months ended September 2025.
Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets.
The company reported a 27.7% increase in consolidated net profit to Rs 261.48 crore on a 22.5% rise in net sales to Rs 1,695.36 crore in Q3 FY26 as compared with Q3 FY25.
The counter slipped 3.26% to Rs 1,736.60 on the BSE.
Gland Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 1857, up 1.13% on the day as on 10:24 IST on the NSE. The benchmark NIFTY is down around 0.21% on the day, quoting at 25670.3. The Sensex is at 83238.9, down 0.25%. Gland Pharma Ltd has gained around 10.48% in last one month.
Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has gained around 1.57% in last one month and is currently quoting at 22494.9, down 0.05% on the day. The volume in the stock stood at 20707 shares today, compared to the daily average of 2.63 lakh shares in last one month.
The PE of the stock is 25.46 based on TTM earnings ending December 25.
Gland Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 1856, up 1.07% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.04% on the day, quoting at 25713.95. The Sensex is at 83408.99, down 0.05%. Gland Pharma Ltd has risen around 10.42% in last one month.
Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has risen around 1.73% in last one month and is currently quoting at 22494.9, up 0.1% on the day. The volume in the stock stood at 53785 shares today, compared to the daily average of 2.63 lakh shares in last one month.
Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/ mL) Single-Dose Bags.
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/ mL) of InfoRLife.
This Product is indicated to treat Hypercalcemia of Malignancy and Multiple Myeloma and Bone Metastases of Solid Tumors.
According to IQVIA, the product had US sales of approximately USD 6.7 million for the twelve months ending November 2025.
Zoledronic Acid Injection is indicated for the treatment of hypercalcemia of malignancy, multiple myeloma, and bone metastases of solid tumors.
According to IQVIA data, the product recorded US sales of approximately $6.7 million during the twelve months ended November 2025.
The counter shed 0.48% to Rs 1,840.95 on the BSE.
Gland Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 1852, up 2.88% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.5% on the day, quoting at 25293. The Sensex is at 82170.1, down 0.48%. Gland Pharma Ltd has added around 7.55% in last one month.
Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has added around 4.67% in last one month and is currently quoting at 21564, up 0.46% on the day. The volume in the stock stood at 3.46 lakh shares today, compared to the daily average of 2.85 lakh shares in last one month.
The PE of the stock is 24.98 based on TTM earnings ending December 25.